GlaxoSmithKline (GSK) and Innoviva have initiated a Phase III Captain study of a triple combination therapy consisting of fluticasone furoate / umeclidinium / vilanterol (FF/UMEC/VI) compared to dual combination therapy of Relvar / Breo (FF/VI) to treat asthma.

Fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium, a long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta-adrenergic agonist (LABA), all three of which are delivered through GSK’s Ellipta dry powder inhaler.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Innoviva CEO Mike Aguiar said: “Closed triple therapy may provide a new once-a-day treatment option for asthma patients not adequately controlled by existing therapy.

“If successful, this would further expand the portfolio of respiratory therapy products delivered via the Ellipta inhaler for the treatment of asthma and COPD.”

"If successful, this would further expand the portfolio of respiratory therapy products delivered via the Ellipta inhaler for the treatment of asthma and COPD."

The Phase III Clinical study of Asthma Patients receiving Triple therapy through A single Inhaler (CAPTAIN) is being conducted as a randomised, double-blind, active controlled, six-arm parallel group, global multicentre study to evaluate FF/UMEC/VI against FF/VI for treating patients whose asthma is inadequately controlled despite treatment with maintenance asthma medication.

The study is planning to enrol 2,250 patients, out of which 375 will be randomly divided into six treatment arms.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

It is primarily focused on determining the baseline change in trough Forced Expiratory volume in one second (FEV1) after completing 24 weeks of treatment.

The secondary endpoint of the trial is to determine the rate of moderate / severe asthma exacerbations on an annual basis. Other secondary endpoints are to evaluate quality of life and symptom control as a result of the triple combination therapy.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact